Sun Pharmaceutical to Acquire Organon for $11.75 Billion at $14 Per Share
Sun Pharmaceutical Industries will acquire Organon for $14.00 per share in an all-cash deal valuing the company at about $11.75 billion. Organon shares jumped 17.01% on the announcement, while a board investigation probes potential undervaluation ahead of expected closing in early 2027.
1. Deal Terms and Valuation
Sun Pharmaceutical Industries agreed to buy Organon for $14.00 per share in an all-cash transaction, implying an enterprise value of approximately $11.75 billion. The offer represents a premium over recent trading levels and secures full ownership of Organon's global healthcare portfolio.
2. Share Price Reaction
Organon shares surged 17.01% following the announcement, lifting the stock to $13.18 at market close. The strong market response underscores investor confidence in the deal’s valuation and anticipated synergies.
3. Board Investigation
A legal firm has launched an investigation into Organon’s board members, examining whether fiduciary duties were met and if the $14 per share proposal undervalues the company’s assets and future growth prospects.
4. Strategic Rationale and Timeline
The acquisition positions Sun Pharmaceutical Industries for expansion in the women's health sector and entry into the biosimilars market. The transaction is slated to close in early 2027, pending regulatory approvals and customary closing conditions.